New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Novo Nordisk A/S

NVO

Healthcare Drug Manufacturers General

Novo Nordisk A/S’s revenue for fiscal 2025 (year ended December 2025) was $46.8 billion, up 11.1% from fiscal 2024.

Revenue
+3.87%
EPS
−17.1%
Free cash flow
−14.8%
Total debt
+30.7%

Quarter to September 2026, against a year earlier

38.69 0.20 −0.51%
Market cap
$128.6B
P/E
9.8×
Fwd P/E FY26e
—
Dividend yield
4.62%
F-score
5/9
ROIC
29.6%
Net debt / EBITDA
0.7×
Payout ratio
0.5×

Latest quarter Q3 FY2026 · quarter to September 2026

Revenue growth has slowed two quarters running, from 37.6% to 3.90%.

Q3 FY2026 and the seven quarters before it
Quarter Revenue, $m Growth, % Op. margin, % EPS, $
Q3 FY26 12,196 3.9 29.1 0.58
Q2 FY26 12,213 4.5 34.5 0.74
Q1 FY26 15,162 37.6 61.6 1.71
Q4 FY25 12,343 0.7 41.0 0.94
Q3 FY25 11,741 11.7 31.6 0.70
Q2 FY25 11,690 19.0 43.5 0.91
Q1 FY25 11,018 15.8 49.7 0.92
Q4 FY24 12,261 28.7 42.8 0.91

Against the consensus: revenue beat by 7.07% ($12.2B v $11.4B); adjusted EPS beat by $0.08 ($0.89 v $0.81).

Growth is on the same quarter a year earlier, and EPS is diluted. Negative figures in brackets.

Reports Feb 3, 2027 · Dec 2026 · consensus EPS $0.68

All quarters →

Capital & Financial Ratios $m

Size
Market Cap 128,620
Revenue ttm 51,914
Net income ttm 16,967
Free cash flow ttm 6,879
Net debt Q 13,171
Valuation
P/E 9.8
Forward P/E FY26e —
Price / sales 3.3
Forward P/S FY26e Powerpack
Price / FCF 24.9
Price / book 5.1
Financial health
Current ratio Q 0.8 (below 1: weak)
Debt / equity Q 0.6
Interest coverage Q 20.3
Growth
Revenue growth FY26e —
EPS growth FY26e −5.3% (below 0%: weak)
EPS growth FY27e −1.5% (below 0%: weak)
EPS growth, 5 yrs e +0.2%
Insiders
Owned by insiders 24.0%

Green and red mark values outside typical ranges; (Q) is the latest quarter; e marks analysts’ estimates, FY26e the fiscal year ending in 2026; n/m is not meaningful, as a P/E on a loss. How we judge →

Compound annual growth

10y 5y 3y
Sales 11.29% 19.20% 23.15%
Cash Flow 12.21% 17.77% 17.31%
Earnings 11.57% 19.16% 25.41%
Book Value 15.44% 24.81% 35.45%

Valuation

P/E against its own 10 years 1.64%
10-year low 10-year high
P/S against its own 10 years 0.91%
10-year low 10-year high
P/B against its own 10 years 0.84%
10-year low 10-year high
EV/Sales against its own 10 years 0.62%
10-year low 10-year high
EV/FCF against its own 10 years 43.92%
10-year low 10-year high

Dividends raised 7 years running

Yield
4.62%
Annual rate
1.80
Payout ratio
45.2%
Growth, 2018–26
+13.9%/yr
  1. 0.63 ’18
  2. 0.61 ’19 −3
  3. 0.65 ’20 +6
  4. 0.74 ’21 +13
  5. 0.80 ’22 +9
  6. 1.03 ’23 +29
  7. 1.45 ’24 +41
  8. 1.73 ’25 +19
  9. 1.80 ’26 +4
paid change on the year, %

Analysts’ price targets Wall Street, collected weekly

Analyst price targets

Analysts’ consensus Wall Street average, updated each weekday

2.8
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 16,611 16,967 17,099 18,291 19,448 22,401 25,057 33,724 42,108 46,792 51,914 +12.2% — — — —
Gross margin, % 84.63 84.21 84.25 83.54 83.51 83.20 83.92 84.60 84.67 80.98 80.89 (3.7) pt
EBT 7,103 7,394 7,280 7,278 8,140 9,400 9,779 15,199 18,443 19,764 22,619 +12.0%
EBT margin, % 42.76 43.58 42.58 39.79 41.85 41.96 39.03 45.07 43.80 42.24 43.57 (0.5) pt
Net income 5,636 5,792 5,906 5,839 6,456 7,598 7,862 12,151 14,643 15,509 16,967 +11.9%
Per share, $
Per share, $ Revenue 3.28 3.43 3.53 3.85 4.17 4.88 5.53 7.52 9.45 10.53 11.78 +13.8%
Earnings 1.07 1.17 1.27 1.23 1.39 1.66 1.74 2.71 3.29 3.49 3.97 +14.0%
Cash flow 1.42 1.26 1.41 1.48 1.71 1.90 2.47 3.53 3.94 4.06 4.36 +12.4%
Capex (0.24) (0.27) (0.39) (0.35) (0.72) (0.26) (0.46) (1.26) (1.67) (3.07) (2.80) +32.6%
Free cash flow 1.18 1.00 1.02 1.12 0.98 1.65 2.00 2.27 2.27 0.99 1.56 (1.9%)
Book value 1.33 1.53 1.64 1.82 2.08 2.45 2.61 3.45 4.67 6.61 7.61 +19.5%
Shares, m 5,060 4,946 4,839 4,749 4,668 4,594 4,531 4,483 4,454 4,443 4,431 (1.4%)
Valuation, ×
Valuation, × P/E 16.11 23.24 18.21 23.53 25.40 33.84 39.47 37.75 26.15 14.66 9.80 25.8
P/S 5.47 7.89 6.52 7.51 8.38 11.48 12.38 13.57 9.10 4.83 3.30 8.7
P/B 13.51 17.70 14.07 15.92 16.81 22.86 26.24 29.58 18.41 7.69 5.11 18.3
EV/Sales 5.28 7.72 6.38 7.42 8.36 11.54 12.38 13.55 9.34 5.15 3.55 8.7
EV/FCF 14.74 26.51 22.16 25.47 35.54 34.12 34.16 44.95 38.94 54.86 26.82 33.1
Cash, $m
Cash, $m Operating cash flow 7,179 6,253 6,822 7,013 7,959 8,751 11,170 15,813 17,540 18,032 19,207 +10.8%
Capex (1,227) (1,312) (1,896) (1,683) (3,382) (1,175) (2,089) (5,648) (7,440) (13,643) (12,328) +30.7%
Free cash flow 5,952 4,941 4,926 5,330 4,577 7,576 9,081 10,166 10,101 4,389 6,879 (3.3%)
Balance, $m
Balance, $m Working capital 1,832 1,978 750 521 (684) (2,215) (1,805) (4,357) (8,211) (6,542) (5,957) n/m
Net debt (3,120) (2,956) (2,343) (1,676) (368) 1,188 (73) (808) 10,172 14,733 13,171 n/m
Shareholders’ equity 6,727 7,567 7,926 8,633 9,701 11,256 11,822 15,473 20,805 29,379 33,542 +17.8%
Returns, %
Returns, % ROA 40.03 38.56 36.36 32.65 31.47 28.59 24.15 30.44 25.87 20.71 20.52 (19.3) pt
ROIC 124.72 100.83 80.88 70.67 55.53 46.86 56.35 63.48 37.55 27.38 29.63 (97.3) pt
ROE 82.18 81.04 76.24 70.52 70.42 72.51 68.14 89.04 80.73 61.81 58.84 (20.4) pt
People
People Employees 41,971 42,076 43,202 43,258 45,323 45,000 55,185 63,370 77,349 69,505 — +5.8%
Revenue/emp, $m 0.40 0.40 0.40 0.42 0.43 0.50 0.45 0.53 0.54 0.67 — +6.1%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated Nov 18, 2026

Novo Nordisk A/S vs peers in Drug Manufacturers General (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
NVS Novartis AG $277.7B 28.8× 24.0× FY26e +4.67% (above 0%: growing) −68.81% (below 0%: shrinking) −17.81% (below 0%: shrinking) 75.99% 12.26% Compare
AZN AstraZeneca PLC $272.1B 24.6× 24.2× FY26e +6.70% (above 0%: growing) +23.46% (above 0%: growing) +1.99% (above 0%: growing) 81.82% 27.07% Compare
AMGN Amgen Inc. $237.4B 25.2× 24.0× FY26e +8.45% (above 0%: growing) +19.39% (above 0%: growing) −13.98% (below 0%: shrinking) 73.10% 35.79% Compare
GILD Gilead Sciences, Inc. $207.8B — (loss-making) — (loss-making) +6.83% (above 0%: growing) −20.16% (below 0%: shrinking) +21.13% (above 0%: growing) 81.07% 41.71% Compare
PFE Pfizer Inc. $158.2B 38.8× 18.7× FY26e −0.43% (below 0%: shrinking) −9.68% (below 0%: shrinking) +20.02% (above 0%: growing) 75.71% 22.14% Compare
NVO Novo Nordisk A/S $128.6B 9.8× — +3.87% (above 0%: growing) −17.14% (below 0%: shrinking) −14.75% (below 0%: shrinking) 76.97% 29.06%
BMY Bristol Myers Squibb Company $119.3B 12.9× 12.0× FY26e +6.93% (above 0%: growing) −2.78% (below 0%: shrinking) −35.95% (below 0%: shrinking) 68.28% 19.40% Compare
SNY Sanofi $111.3B 22.8× — +13.89% (above 0%: growing) +8.21% (above 0%: growing) +99.60% (above 0%: growing) 76.16% 28.53% Compare
GSK GSK PLC Sponsored ADR $95.9B 16.4× 15.5× FY26e +3.75% (above 0%: growing) −23.88% (below 0%: shrinking) +62.44% (above 0%: growing) 73.11% 23.93% Compare
Median of peers $183.0B 24.6× 21.4× +6.77% −6.23% +11.01% 75.85% 25.50%

All 21 Drug Manufacturers General stocks →

Novo Nordisk A/S (NVO) Latest News

What happened

  1. Deal Novo Nordisk and nference partnered to use clinical-trial research and an AI platform to study cardiometabolic disease and healthy ageing.
  2. Product Novo Nordisk submitted US and European applications for etavopivat, an investigational sickle cell treatment that reduced vaso-occlusive crises by 27% in a Phase 3 trial.
  3. Product Novo Nordisk’s Wegovy pill surpassed eight million cumulative US prescriptions, while third-quarter sales reached DKK 5.4 billion.
  4. Legal Novo Nordisk was among the GLP-1 manufacturers asked by the FDA to add warnings about rare sudden vision loss from NAION.
  5. Results Novo Nordisk reported third-quarter sales of DKK 79.2 billion and raised its 2026 adjusted sales and operating profit growth outlook to -2% to 2%.
12 more headlines
All NVO news, as stories →

NVO metrics, ten years each

stockrow.com/NVO · Data as of Nov 18, 2026 · For information only; not investment advice. · © 2026 stockrow.com